ASND Earnings & Financial Statements
Ascendis Pharma A/S
$227.00
+$3.79(+1.70%)
38
Overall
20
Value
27
Tech
68
Quality
Market Cap
$14.96B
Volume
995.63K
52W Range
$186.05 - $282.15
Target Price
$314.75
ASND earnings and financial statements: Ascendis Pharma A/S's income statement, balance sheet and cash flow statement, annual and quarterly.
ASND Annual Financial Statements
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | $363.64M | $266.72M | $51.17M | $7.78M | $6.95M |
| Cost of revenue | $44.26M | $44.40M | $12.14M | $3.52M | $80.84M |
| Operating income | -$278.76M | -$455.54M | -$561.81M | -$451.79M | -$411.46M |
| EBITDA | -$282.65M | -$423.51M | -$590.54M | -$368.61M | -$411.69M |
| Net income | -$378.08M | -$493.79M | -$583.19M | -$379.72M | -$419.00M |
| EPS (diluted) | $-6.53 | $-8.55 | - | - | $-8.28 |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total assets | $1.18B | $825.59M | $1.09B | $531.09M | $280.00M |
| Total liabilities | $1.29B | $971.28M | $826.39M | $316.49M | $263.58M |
| Shareholders’ equity | -$105.71M | -$145.70M | - | - | - |
| Cash and equivalents | $559.54M | $392.16M | $22.93M | $38.34M | $9.18M |
| Long-term debt | $365.08M | $223.00M | $482.96M | $97.97M | $85.12M |
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating cash flow | -$306.20M | -$467.36M | -$495.70M | -$417.65M | -$271.55M |
| Capital expenditure | - | - | -$228.33M | -$249.74M | -$557.61M |
| Free cash flow | -$306.67M | -$469.75M | -$724.03M | -$667.39M | -$829.16M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ASND | $227.00 | +1.7% | 995.63K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |